Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email in the first instance.

 Information  X 
Enter a valid email address

Oxford Glycosciences (OGS)

  Print      Mail a friend

Wednesday 20 June, 2001

Oxford Glycosciences

Re Agreement

Oxford Glycosciences PLC
20 June 2001

For further information, please contact:

For Oxford GlycoSciences Plc               For NeoGenesis
Michael Kranda, Chief Executive Officer    Allen Michaels
Prof. Raj Parekh, Chief Scientific Officer Chairman and Chief Executive Officer
Tel: +44 (0) 1235 208000                   Dr. Satish Jindal
                                           President & Chief Scientific Officer
UK: Financial Dynamics                                   Tel: +1 (617) 868 1500
David Yates / Melanie Toyne Sewell
Tel: +44 (0) 207 831 3113                  Schwartz Communications, Inc.
                                           Nigel Smith - Tel: +1 (781) 684 6500

USA: Feinstein Kean
Michael Lawson - Tel: +1 (617) 761-6765

                 OGS and NeoGenesis Announce High-Throughput,
                     'Target-to-Drug Lead' Collaboration

Oxford, UK/Cambridge, Mass - 20 June 2001 - Oxford GlycoSciences Plc ('OGS')
(LSE: OGS, NASDAQ: OGSI) today entered into a collaboration with NeoGenesis
Inc., a privately held biotech company based in Cambridge, Massachusetts.
This alliance is expected to accelerate OGS' discovery and development of
small molecule drugs against protein targets derived from its high-throughput
proteomics platform.  NeoGenesis' chemical genomics technology platform is a
logical complement to the thousands of disease-associated proteins identified
by OGS, and both companies expect the deal to increase drug candidate output
and shorten the time to clinic.

Central to NeoGenesis' chemical genomics drug discovery platform is the
company's core technology, the Automated Ligand Identification System ('ALIS'). 
ALIS is a scalable system for rapidly screening large numbers of
disease-associated targets. Coupled with NeoGenesis' neoMorph compound '
library', consisting of more than 10 million diverse 'drug-like' compounds,
ALIS identifies small molecule ligands of high affinity and high selectivity
against the full range of protein classes to accelerate drug discovery.

Under the terms of the agreement, OGS will provide a large number of potential
protein targets it has identified.  In turn, NeoGenesis will apply its
high-throughput integrated technologies for chemistry, screening and
computational biology to search for lead compounds. OGS will also provide
NeoGenesis with research funding, milestone payments and royalties on drug
candidates and resultant products. Finally, OGS will commercialise all drug
candidates and products, and is acquiring an equity stake in NeoGenesis.
Detailed financial terms of the agreement have not been disclosed.

'Conventional drug discovery technologies are underpowered to leverage the
scale and nature of targets emerging from proteomics research,' said Dr. Raj
Parekh, Chief Scientific Officer of OGS.  'Our collaboration with NeoGenesis
will give us the means to discover rapidly lead compounds against a large
number of protein targets, so reducing time to clinical development.  A key
requirement to fulfill the genome-to-drug paradigm is to obtain clinical leads
rapidly against genomics and proteomics targets and use these leads both to
validate the target and to serve as drug candidates in themselves.'

'OGS is a recognised leader in proteomics-based drug research,' said Satish
Jindal, Ph.D., president and CSO of NeoGenesis.  'By combining OGS'
high-throughput protein discovery with NeoGenesis' high-throughput lead
discovery technologies the collaboration has the potential to yield many
important new drugs.  The OGS partnership is a significant addition to our
drug discovery and development programme, and also it has the potential to
provide NeoGenesis with milestone payments and royalties from profits
generated by future products.'

'OGS is identifying a large portfolio of disease associated proteins,' said
Michael Kranda, Chief Executive Officer of OGS. 'To capitalise on the
potential that this represents, we've enlisted the large chemical libraries
and high-speed screening technology of NeoGenesis, which is a great match for
OGS' high-throughput proteomics platform.  Together, I believe our two
companies can set a new standard for fast and cost-effective drug discovery.
This collaboration, together with the monoclonal antibody-based relationship
with Medarex, confirms OGS' commitment to discovering and developing drugs
from the protein targets identified by our proteomics platform.'


There will an analysts conference call on Wednesday 20 June at 11am (UK time).
For further details, please contact Claire Rowell on 0207 269 7285.

About OGS

OGS has developed a proprietary technology for the comprehensive study of
proteins, integrating proteomics with genomics to create an innovative drug
discovery platform. OGS's proteomics collaborations with major pharmaceutical
and biotechnology companies include Bayer, GlaxoSmithKline, Medarex, Pioneer
Hi Bred/Du Pont and Pfizer. OGS has technology development collaborations with
Applera, Cambridge Antibody Technology, Packard BioScience and the Institute
for Systems Biology.  Most recently, OGS has formed a £30 million joint
venture with Marconi plc, called Confirmant.

OGS has drug research discovery programmes in cancer, infectious disease and
glycolipid storage disorders. OGS' most advanced drug candidate, VevescaTM, is
currently undergoing clinical trials for the treatment of Gaucher disease.
VevescaTM has received 'fast track' designation from the FDA and has been
granted orphan drug status by both the FDA and the European Commission for the
treatment of Gaucher disease.  OGS expects to file a new drug application for
the oral treatment of Gaucher disease in mid-2001. VevescaTM is an
investigational drug and has not received approval for marketing in any

About NeoGenesis

NeoGenesis is a leader in developing drug discovery technologies that enable
pharmaceutical and biotechnology companies to identify more and better drug
leads and drug targets from the genome in far less time than conventional
technologies.  NeoGenesis' chemical genomics technology addresses critical and
complex barriers in genomics drug discovery by facilitating an efficient and
highly scalable method for discovery of new drugs from thousands of proteins
that genomics and proteomics technologies are yielding.  NeoGenesis is
creatively solving the 'chokepoint' problem of the incompatibility of current,
slow drug discovery processes with the diversity and volume of the proteome.

Founded in 1997 and headquartered in Cambridge, Mass., NeoGenesis has quickly
developed partnerships and collaborative research agreements with leading
biopharmaceutical companies, including; Merck, Schering Plough, Biogen and
Microcide.  NeoGenesis is privately held and has raised more than $40 million
in funding from venture, institutional and private investors. Current
investors include; OrbiMed Advisors LLC of New York, Ft. Washington Private
Equity Investors, Essex Street Associates and Valentine Partners.

This press release contains forward-looking statements, such as the success of
the collaboration between OGS and NeoGenesis, including the acceleration of
OGS' discovery and development of drugs, an increase in drug candidates,
shrinking the time to clinic, commercialising drug candidates and products,
yielding many important new drugs and setting a new standard for fast and cost
effective drug development, filing an NDA for VevescaTM and the success of
VevescaTM as a treatment of Gaucher disease.  Factors that could cause actual
results to vary significantly from those expressed or implied by these and
other forward-looking statements include the success of OGS' and NeoGenesis'
competitors' products and technologies, the success of OGS' and NeoGenesis'
research and development strategies, the validity of OGS' and NeoGenesis'
technologies and intellectual property positions and strategies, the
successful and timely completion of clinical studies and uncertainties related
to the regulatory process.